Radiotherapy for patients with isolated local recurrence of primary resected pancreatic cancer: Prolonged disease-free interval associated with favorable prognosis

Strahlentherapie und Onkologie

Volumn 190, Issue 5, 2014, Pages 485-490

  Nakamura, Akira ^a   Itasaka, Satoshi ^a   Takaori, Kyoichi ^a   Kawaguchi, Yoshiya ^a   Shibuya, Keiko ^b   Yoshimura, Michio ^a   Matsuo, Yukinori ^a   Mizowaki, Takashi ^a   Uemoto, Shinji ^a   Hiraoka, Masahiro ^a  

^a KYOTO UNIVERSITY   (Japan)

^b YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemoradiation therapy; Isolated local recurrence; Pancreatic cancer; Prognostic factor; Toxicity

Indexed keywords

GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CLINICAL ARTICLE; DISEASE FREE INTERVAL; FEMALE; HUMAN; MALE; METASTASIS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIATION DOSE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CHEMORADIOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OXONIC ACID; PAIN MEASUREMENT; PALLIATIVE CARE; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROGNOSIS; RADIOTHERAPY DOSAGE; TEGAFUR;

EID: 84900808851     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-014-0610-8     Document Type: Article

References (28)

1. Combs SE, Habermehl D, Kessel K et al (2013) Intensity modulated radiotherapy as neoadjuvant chemoradiation for the treatment of patients with locally advanced pancreatic cancer: outcome analysis and comparison with a 3D-treated patient cohort. Strahlenther Onkol 189:738-744
2. Habermehl D, Brecht IC, Bergmann F et al (2013) Chemoradiation in patients with isolated recurrent pancreatic cancer therapeutical efficacy and probability of re-resection. Radiat Oncol 8:27
3. Haeno H, Gonen M, Davis MB et al (2012) Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 148:362-375
4. Hamidian Jahromi A, Sangster G, Zibari G et al (2013) Accuracy of multi-detector computed tomography, fluorodeoxyglucose positron emission tomography-CT, and CA 19-9 Levels in detecting recurrent pancreatic adenocarcinoma. JOP 14:466-468
5. Hashimoto K, Ueno H, Ikeda M et al (2009) Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment? Oncology 77:217-223
6. Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362:1605-1617
7. Hishinuma S, Ogata Y, Tomikawa M et al (2006) Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg 10:511-518
8. Iacobuzio-Donahue CA, Fu B, Yachida S et al (2009) DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 27:1806-1813
9. Kalser MH, Ellenberg SS (1985) Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120:899-903
10. Kleeff J, Reiser C, Hinz U et al (2007) Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg 245:566-572
11. Klinkenbijl JH, Jeekel J, Sahmoud T et al (1999) Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230:776-782, discussion 782-784
12. Neoptolemos JP, Dunn JA, Stocken DD et al (2001) Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 358:1576-1585
13. Neoptolemos JP, Stocken DD, Friess H et al (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200-1210
14. [no authors listed] (1987) Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer 59:2006-2010
15. Oshima M, Okano K, Muraki S et al (2013) Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. Ann Surg 258:336-346
16. Regine WF, Winter KA, Abrams RA et al (2008) Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 299:1019-1026
17. Seelig MH, Janot M, Chromik AM et al (2009) Redo-surgery following curative resection of pancreatic carcinoma: the difference between true and suspected recurrence. Dig Surg 26:222-228
18. Strobel O, Hartwig W, Hackert T et al Re-resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with encouraging survival. Ann Surg Oncol 20:964-972
19. Tempero MA, Arnoletti JP, Behrman SW et al (2012) Pancreatic adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 10:703-713
20. Therneau TM, Grambsch PM, Fleming TR (1990) Martingale-based residuals for survival models. Biometrika 77:147-160
21. Thomas RM, Truty MJ, Nogueras-Gonzalez GM et al (2012) Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. J Gastrointest Surg 16:1696-1704.
22. Van den Broeck A, Sergeant G, Ectors N et al (2009) Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol; 35:600
23. Van Laethem JL, Hammel P, Mornex F et al (2010) Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol 28:4450-4456
24. Wilkowski R, Thoma M, Bruns C et al (2006) Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer. JOP 7:34-40
25. Winter JM, Tang LH, Klimstra DS et al (2013) Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to SMAD4 expression. Ann Surg 258:331-335
26. Yoon H, Oh D, Park HC et al (2013) Predictive factors for gastroduodenal toxicity based on endoscopy following radiotherapy in patients with hepatocellular carcinoma. Strahlenther Onkol 189:541-546
27. Zamboglou C, Messmer MB, Becker G et al (2012) Stereotactic radiotherapy in the liver hilum. Basis for future studies. Strahlenther Onkol 188:35-41
28. Zhang Y, Frampton AE, Kyriakides C et al (2012) Loco-recurrence after resection for ductal adenocarcinoma of the pancreas: predictors and implications for adjuvant chemoradiotherapy. J Cancer Res Clin Oncol 138:1063-1071